Itulazax (Betula Verrucosa (108))

Betula Verrucosa provides the specific birch pollen proteins that, when administered repeatedly under the tongue, shift the immune response from an IgE‑driven allergy toward a protective IgG4 and regulatory T‑cell profile. This re‑education of the immune system promotes long‑term tolerance and diminishes allergic reactions upon natural exposure.

The dosing regimen for Itulazax is individualized by the prescribing clinician based on the patient’s sensitivity, age, and treatment goals. The prescriber determines the starting concentration, escalation schedule, and maintenance dose, ensuring safe and effective immunotherapy tailored to each patient.

Safety data for Itulazax in pregnancy and lactation are limited. Because the product is a biologic allergen extract, clinicians generally recommend weighing potential benefits against unknown risks. Pregnant or breastfeeding individuals should discuss use with their healthcare provider before starting therapy.

To request Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Itulazax is a sublingual formulation, offering the convenience of at‑home administration after the initial supervised dose, unlike subcutaneous injections that require clinic visits. Its allergen extract is standardized to Betula Verrucosa, providing a comparable efficacy profile to other birch pollen extracts while reducing injection‑related discomfort.

Itulazax should be stored at room temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not refrigerate or freeze unless specifically instructed by the manufacturer.

Itulazax is taken sublingually. The patient places the prescribed dose under the tongue and holds it there for the time specified by the prescriber, usually a few minutes, before swallowing. The first dose is administered in a medical setting to monitor for any immediate reactions.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe angioedema, and respiratory distress. These events are rare but require immediate medical attention. Patients should be educated on recognizing early signs and have emergency medication, such as epinephrine, readily available if prescribed.

Itulazax is contraindicated in individuals with a history of severe systemic reactions to birch pollen extracts, uncontrolled asthma, severe immunodeficiency, or those receiving beta‑blockers or ACE inhibitors without close medical supervision. Pregnant or breastfeeding women should only use it after a thorough risk‑benefit discussion with their clinician.